Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Roth Capital analyst Max Masucci initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $3.5.
Roth Capital analyst Max Masucci initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $3.5.